Related Experiment Video
Updated: Jun 16, 2026
07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Monascus purpureus Went rice in nephrotic hyperlipidemia
Indian Journal of Nephrology
|February 10, 2010
Summary
Monascus purpureus Went rice and fluvastatin effectively manage nephrotic dyslipidemia by reducing cholesterol. Both treatments were well-tolerated, showing no significant side effects, making Monascus purpureus Went rice a safe and economical option.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Nephrotic dyslipidemia is a significant risk factor for systemic atherosclerosis and can worsen glomerular disease progression.
- Understanding effective management strategies for nephrotic dyslipidemia is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of Monascus purpureus Went rice compared to fluvastatin in treating nephrotic dyslipidemia.
- To assess the impact of these interventions on lipid profiles and neuromuscular function.
Main Methods:
- A randomized controlled trial involving 72 patients with persistent idiopathic nephrotic syndrome and secondary dyslipidemia.
- Patients were assigned to receive Monascus purpureus Went rice, fluvastatin, or no antidyslipidemic therapy (control).
- Comprehensive laboratory investigations, including renal function tests and lipograms, were performed. Neuromuscular status was assessed using electromyography and nerve conduction velocity.
Main Results:
- Both Monascus purpureus Went rice and fluvastatin were well-tolerated, with no significant adverse effects reported, including on neuromuscular functions.
- Both treatment groups demonstrated significant reductions in cholesterol levels at 6 months and 1 year compared to the control group.
Conclusions:
- Monascus purpureus Went rice presents a safe, effective, and economical therapeutic strategy for managing nephrotic dyslipidemia.
- The findings support the use of Monascus purpureus Went rice as an alternative treatment for patients with nephrotic dyslipidemia.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...